Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530822 | 0.79 | NPC1 (0.38) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL3923413 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL20658802 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL15671484 | 0.78 | EGLN1 (0.57) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL2159890 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL3149078 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| Bromide SCHEMBL6694084 | 0.76 | ALKBH2 (0.55) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL16566387 | 0.76 | ALKBH2 (0.33) | ALKBH2EGLN1 | |
| SCHEMBL12075257 | 0.75 | ALKBH2 (0.54) | ALKBH2EGLN1GRM4DRD2DRD4 | |
| SCHEMBL23872054 | 0.74 | ALKBH2 (0.53) | ALKBH2EGLN1GRM4DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114316222-B | Polymer rich in aromatic ring structure, and preparation method and application thereof | 盐城工学院 | 2024-05-28 | — | — | CN | claimed |
| CN-114316222-A | Polymer rich in aromatic ring structure and preparation method and application thereof | 盐城工学院 | 2022-04-12 | — | — | CN | claimed |
| CN-114316222-B | Polymer rich in aromatic ring structure, and preparation method and application thereof | 盐城工学院 | 2024-05-28 | — | — | CN | disclosed |
| CN-114316222-B | Polymer rich in aromatic ring structure, and preparation method and application thereof | 盐城工学院 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023283523-A1 | 2,3-DIHYDROBENZO[B][L,4]DIOXIN-6-YL CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-12 | — | — | WO | disclosed |
| CN-114316222-A | Polymer rich in aromatic ring structure and preparation method and application thereof | 盐城工学院 | 2022-04-12 | — | — | CN | disclosed |
| CN-114316222-A | Polymer rich in aromatic ring structure and preparation method and application thereof | 盐城工学院 | 2022-04-12 | — | — | CN | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| CN-100387594-C | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2008-05-14 | — | — | CN | disclosed |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. | 2006-08-31 | — | — | US | disclosed |
| CN-1795184-A | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2006-06-28 | — | — | CN | disclosed |
| EP-1613614-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089303-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRM1, GRIK5 | ALKBH2 4743/4885EGLN1 2991/4885GRM4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.